The week in pharma: action, reaction and insight – week to January 6, 2023
By Barbara Obstoj-Cardwell. Editor
Among featured research news last week, US pharma giant Pfizer impressed when it released positive Phase III data on its hemophilia B gene therapy fidanacogene elaparvovec. Italian drugmaker Newron Pharmaceuticals last Monday released what it called “compelling” trial results for its antipsychotic candidate evenamide. Also, Deciphera Pharmaceuticals last Tuesday touted the benefits of its gastrointestinal stromal tumor (GIST) drug Qinlock. Kicking off the 2023 M&A season, US mRNA specialist Moderna last Wednesday announced its first ever full acquisition, that of Japanese firm OriCiro Genomics for $85 million. Fate Therapeutics has terminated its deal with Johnson & Johnson subsidiary Janssen to develop CAR-T cell therapies for cancer targets.
Pfizer says hemophilia B gene therapy controlled bleeding in key study
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze